Financial reports
10-K
2023 FY
Annual report
5 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
10-K
2022 FY
Annual report
8 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
10-K
2021 FY
Annual report
15 Mar 22
10-Q
2021 Q3
Quarterly report
3 Nov 21
Current reports
8-K
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
5 Mar 24
8-K
Other Events
19 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Dec 23
8-K
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
20 Nov 23
8-K
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
9 Nov 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
8-K
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
18 Sep 23
8-K
Submission of Matters to a Vote of Security Holders
7 Sep 23
8-K
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
14 Aug 23
8-K
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma
11 Jul 23
Registration and prospectus
S-8
Registration of securities for employees
7 Mar 24
424B3
Prospectus supplement
31 May 23
S-1
IPO registration
19 May 23
S-3
Shelf registration
15 Mar 23
S-8
Registration of securities for employees
8 Mar 23
424B5
Prospectus supplement for primary offering
15 Jul 22
424B5
Prospectus supplement for primary offering
21 Jun 22
S-8
Registration of securities for employees
15 Mar 22
S-3
Shelf registration
15 Mar 22
424B5
Prospectus supplement for primary offering
22 Jul 21
Proxies
DEF 14A
Definitive proxy
7 Aug 23
PRE 14A
Preliminary proxy
25 Jul 23
DEFA14A
Additional proxy soliciting materials
8 Mar 23
DEF 14A
Definitive proxy
8 Mar 23
PRE 14A
Preliminary proxy
13 Feb 23
DEFA14A
Additional proxy soliciting materials
25 Apr 22
DEF 14A
Definitive proxy
25 Apr 22
DEFA14A
Additional proxy soliciting materials
25 May 21
DEFA14A
Additional proxy soliciting materials
23 Apr 21
DEF 14A
Definitive proxy
23 Apr 21
Other
EFFECT
Notice of effectiveness
1 Jun 23
UPLOAD
Letter from SEC
26 May 23
CORRESP
Correspondence with SEC
26 May 23
EFFECT
Notice of effectiveness
27 Mar 23
CORRESP
Correspondence with SEC
22 Mar 23
UPLOAD
Letter from SEC
21 Mar 23
EFFECT
Notice of effectiveness
29 Mar 22
CORRESP
Correspondence with SEC
24 Mar 22
UPLOAD
Letter from SEC
22 Mar 22
EFFECT
Notice of effectiveness
14 Sep 20
Ownership
SC 13G/A
aaronson wayne
19 Mar 24
4
Scott B. Brown
13 Mar 24
4
CHARLES THEUER
13 Mar 24
SC 13G/A
Lincoln Park Capital Fund, LLC
14 Feb 24
SC 13D/A
Opaleye Management Inc.
9 Feb 24
4
Change in insider ownership
14 Nov 23
SC 13G
Lincoln Park Capital Fund, LLC
2 Jun 23
4
CHARLES THEUER
28 Apr 23
4
Lisa Johnson-Pratt
21 Apr 23
4
Carol C. Lam
21 Apr 23